Advanced clinical trials of dendritic cell vaccines in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-27 / J. Investig. Med. 2020 Jul;Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-13 / Immunol. Invest. 2020 Jul;:1-18Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-04-22 / Curr. Opin. Biotechnol. 2020 Apr;65:190-196A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-11-26 / J Transl Med 2019 11;17(1):391Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-11-25 / J Immunol Res 2019;2019:9631515Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer
/in Hyperthermia, International Publications, Ovarian Cancer /von 2019-09-01 / Jpn. J. Clin. Oncol. 2019 Sep;49(9):832-838A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).
/in Hyperthermia, International Publications, Ovarian Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17032)Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-04-11 / Front Immunol 2019;10:766Immunotherapy in Ovarian Cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-04-05 / Surg. Oncol. Clin. N. Am. 2019 Jul;28(3):447-464
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
- Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma; a single center phase I/II trial
- MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells